Appendix 3Y - Directors on-market purchase of shares
Filed with ASX · · 10 pages · English
Proteomics International Laboratories Ltd. on 6ix
Earlier from Proteomics International Laboratories
- Big pharma clinical study validates PromarkerD kidney test
- Updated Investor Presentation
- Proteomics International receives COVID-19 research grants
- Appendix 4C and Quarterly Report - March 2020
- CE Mark for Proteomics PromarkerD Immunoassay Kit
Later from Proteomics International Laboratories
- PromarkerD Intellectual Property portfolio expands
- June 2020 Quarterly Activities Report and Appendix 4C
- Partnership with QIMR Berghofer targets oesophageal cancer
- First distribution agreement for PromarkerD immunoassay
- Proteomics International raises $6m in successful Placement
Follow Proteomics International Laboratories into a list and get an email when it puts out news.
Follow Proteomics International Laboratories